Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia

Summary, in English

We have analyzed the M-bcr breakpoint position in 133 Philadelphia-positive chronic myeloid leukemia patients and correlated the findings with clinical, hematologic, and cytogenetic data. We also investigated the splicing pattern of the BCR-ABL mRNA in 30 patients, using reverse transcriptase PCR. No statistically significant differences were found between breakpoint position within M-bcr and clinical parameters at diagnosis, the karyotypic evolution pattern, or the leukemic phenotype during blast crisis. Furthermore, the breakpoint position within M-bcr did not correlate with the duration of chronic phase or survival time. When the splicing pattern of the BCR-ABL mRNA was compared with the results of the genomic breakpoint mapping, it was found that approximately 60% (8/14) of the patients with a 5' break expressed b2a2 fusion mRNA, whereas all patients (10/10) with a 3' break expressed b3a2 BCR-ABL mRNA.

• Author: Thoas Fioretos; Per-Gunnar Nilsson; P Åman; Sverre Heim; Ulf Kristoffersson; C Malm; B Simonsson; Ingemar Turesson; Felix Mitelman
• Department/s: Division of Clinical Genetics; Division of Hematology and Clinical Immunology; Department of Clinical Sciences, Malmö
• Publishing year: 1993
• Language: English
• Pages: 1225-1231
• Publication/Series: Leukemia
• Volume: 7
• Issue: 8
• Document type: Journal article
• Publisher: Nature Publishing Group
• Topic: Cancer and Oncology
• Status: Published
• ISBN/ISSN/Other: ISSN: 1476-5551